Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KRTEV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
B43-genistein
|
|||||
| Synonyms |
B43-genistein
Click to Show/Hide
|
|||||
| Organization |
University of Minnesota (Originator);Parker Hughes Cancer Center (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Antibody Name |
Anti-CD19 antibody
|
Antibody Info | ||||
| Antigen Name |
B-lymphocyte antigen CD19 (CD19)
|
Antigen Info | ||||
| Payload Name |
Genistein
|
Payload Info | ||||
| Therapeutic Target |
isoflavone tyrosine kinase
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random Lysines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Acute lymphoblastic leukemia |
1 Trials
|
||||||||
| Unspecific non-hodgkin lymphoma |
1 Trials
|